H.C. Wainwright analyst Raghuram Selvaraju upgraded Idorsia (IDRSF) to Buy from Neutral with a price target of CHF 6, up from CHF 2. The company’s guidance provided a pathway to profitability, driven by European and Canadian market uptake of its marketed anti-insomnia medication daridorexant, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDRSF: